osimertinib
astrazeneca
['sclc', 'nsclc', 'osimertinib']
dr. presents results from phase ii study of neoadjuvant osimertinib for resectable #egfr nsclc at #asco23. mpr rate only 15% (target was 50%) and no pcr after 1-2m of osimertinib. r0 resection achieved in 89% (11% went to crt). 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown, Co-Host Official @IASLC Podcast, #ITYSL, #HereWeGo